SEC Form 4 · accession 0001209191-15-071843
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Kemmerer
Officer — VP, Pharma Dev & Manufacturing
Period of report
Sep 18, 2015
Accepted (ET)
Sep 22, 2015 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2015 | M | 1,000 | $1.342 | A | 11,848 | D | |
| Common Stock | Sep 18, 2015 | S | 1,000 | $12.195 | D | 10,848 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.342 | Sep 18, 2015 | M | 1,000 | D | — | Feb 6, 2024 | Common Stock | 1,000 | 50,182 | D |
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Option shares vest in 48 equal installments measured from the vesting commencement date, 02/06/2014.